As a research center embedded within Kaiser Permanente’s large and dynamic health care system, our investigators have a unique opportunity to apply scientific expertise to real-world clinical problems, translate findings into practice, and share what we learn with the broader community.
Dr. Gary Buchschacher is the director of the Cancer Clinical Trials Access Program. He coordinates and leads the program’s activities and acts as principal investigator for numerous studies. He is the site PI for the Kaiser Permanente Los Angeles Medical Center and a member of its Oncology Steering Committee.
Dr. Buchschacher is the medical oncology lead for the Southern California Permanente Medical Group’s Gastrointestinal Cancer Subcommittee and a member of the Regional Cancer ...
Over the years, clinical trials have led to amazing advances in treatment—even cures—for devastating illnesses. William Towner, MD, FACP, FIDSA, regional physician director for clinical trials, describes how trials at Kaiser Permanente contribute to the development of more effective and safer treatments for diseases such as HIV, hepatitis C, cancer, and more. (2:15)
The Centers for Disease Control and Prevention has selected Kaiser Permanente Southern California as a new site in its U.S. Flu Vaccine Effectiveness network. Kaiser Permanente Southern California is inviting its members to participate in a nationwide study of how well flu and COVID-19 vaccines are working. It is one of 2 new sites selected ...
COVID-19 vaccine recipients had lower non-COVID-19 death rates than people who weren’t vaccinated, according to Kaiser Permanente research published Oct. 22, 2021 in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report. “Despite numerous studies showing the safety of COVID-19 vaccines, some people have remained hesitant to get vaccinated,” said lead author ...
A physician investigator in the Southern California Permanente Medical Group received a grant to study antibody responses to COVID-19 vaccination among health care workers. The study will also help learn more about the impact of booster vaccination and the rates of asymptomatic COVID-19 infection among the vaccinated. Kaiser Permanente Southern California is inviting up to ...
Debbie Malden, DPhil, MSc, is an epidemiologist with research experience in large-scale prospective cohort studies. Before joining Kaiser Permanente, Dr. Malden completed her DPhil at the University of Oxford, assessing risk factors for cardiovascular disease among a half million U.K. adults using both observational and genetic epidemiological techniques. In addition to her research on chronic ...
About 40% of breast cancer survivors use prescription medications to alleviate sleep problems, but these medications can increase their risk of bone fractures, according to research from Kaiser Permanente in Southern California published Sept. 29, 2021 in Breast Cancer Research and Treatment. For many of the 3.8 million breast cancer survivors living in the United States, ...
The October IMPACT newsletter features research about how sleep medications may increase bone fracture risk among breast cancer survivors. Other stories focus on COVID-19 variants and the rise in severity of cases associated with the delta variant this summer, and the association between COVID-19 severity and where you live in relation to busy roads. There’s also a Q&A with Dr. Debbie Malden, an Epidemic Intelligence Service officer with the Centers for Disease Control and Prevention, who is stationed at Kaiser Permanente Southern California.
Investigators with the Division of Biostatistics Research collaborate closely with scientists from the department’s other scientific divisions, as well as physician researchers at medical centers across Kaiser Permanente Southern California. They provide expertise and guidance on study design, power and sample size calculations, data management, data analysis and interpretation, and statistical methodology.
Investigators from the division have expertise in study design and data analysis for observational studies and clinical trials to address study questions. Their expertise spans standard and modern methods that deal with complex and big data for population and causal inferences as well as disease prediction.
Each division has at least one dedicated collaborative biostatistician research scientist assigned to provide statistical guidance on its research studies. In addition, one of the collaborative biostatistician researcher scientists leads the Regional Research Statistical Support team, which supports medical center-based researchers.